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TOPOIIa and HER-2/neu overexpression/ampliﬁcation in Barrett’s oesophagus, dysplasia
and adenocarcinoma
Aims: Topoisomerase IIa (TOPOIIa) and HER-2 ⁄ neu
are chromosome 17q genes coampliﬁed in various
cancers; no data exist for Barrett’s oesophagus (BO)
and BO adenocarcinoma (ADC). The aim was to
investigate gene ampliﬁcation and protein overexpres-
sion of TopoIIa and Her-2 ⁄ neu in non-dysplastic BO,
dysplastic BO, Barrett ADC, and chromosome 17
aneusomy.
Methods and results: Forty-four patients [18 BO, 13 BO
with dysplasia (ﬁve low-grade dysplasia, eight high-
grade dysplasia) and 13 ADC in BO] were evaluated by
immunohistochemistry and ﬂuorescence in situ hybrid-
ization (FISH). Genes (HER-2 ⁄ neu and TOPOIIa) and
chromosome 17 were evaluated by FISH. Patients with
BO, dysplasia and ADC were compared. A signiﬁcant
association was found between TOPOIIa protein over-
expression and TopoIIa gene ampliﬁcation, chromo-
some 17 aneusomy, HER-2 ⁄ neu gene ampliﬁcation and
HER-2 protein overexpression as well as between
HER-2 protein and HER-2 ⁄ neu gene, TopoIIa gene
and aneusomy for chromosome17, and between the
genes TOPOIIa and HER-2 ⁄ neu. Gene ampliﬁcation
(HER-2 ⁄ neu,TOPOIIa),proteinoverexpression(HER-2 ⁄
TOPOIIa), and chromosome 17 aneusomy were asso-
ciated with dysplasia or ADC. Most BO patients showed
no ampliﬁcation ⁄ overexpression ⁄ aneusomy for the
above genes, proteins and chromosome, with no
differences between dysplasia and ADC.
Conclusions: HER-2 ⁄ neu and TOPOIIa ampliﬁcation ⁄
overexpression might discriminate between BO and
dysplasia ⁄ ADC. Chromosome 17 aneusomy is asso-
ciated with dysplasia or ADC in BO.
Keywords: adenocarcinoma, Barrett’s oesophagus, Her-2, TopoIIa
Abbreviations: ADC, adenocarcinoma; BO, Barrett’s oesophagus; CEP17, chromosome enumeration probe 17;
FDA, Food and Drug Administration; FISH, ﬂuorescence in situ hybridization; H&E, haematoxylin and eosin; HGD,
high-grade dysplasia; HPF, high-power ﬁeld; LGD, low-grade dysplasia; SG, Spectrum Green; SO, Spectrum Orange;
TOPOIIa, topoisomerase IIa
Introduction
HER-2 ⁄ neu and topoisomerase IIa (TOPOIIa) genes are
both located on chromosome 17q, and they can be
co-ampliﬁed in cancer.
1 Ampliﬁcation of both genes
has been reported in breast, prostatic, gastric, colorec-
tal and pancreatic carcinomas.
1–5 HER-2 ⁄ neu
oncogene encodes for the human epidermal growth
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prognosis in a variety of tumours.
6,7
There are two isoforms of mammalian topoisomerase
II, a and b. DNA topoisomerase II catalyses a transient
double-strand DNA break, which allows the passage of
another DNA duplex through the break before the
strands are resealed. TOPOIIa represents the target
enzyme for speciﬁc anticancer drugs, such as anthra-
cyclines, commonly used for a variety of both haema-
tological and solid neoplasms, including leukaemias,
lymphomas and breast cancer. In vitro studies have
shown a correlation between the expression level of
TOPOIIa in cancer cells and the sensitivity of those cells
to topoisomerase inhibitors.
8,9
Some authors have suggested a concordance of
HER-2 and TOPOIIa gene ampliﬁcation in breast
cancer,
3 while others have demonstrated that TO-
POIIa ampliﬁcation, identiﬁed by ﬂuorescence in situ
hybridization (FISH), may occur with or without
HER-2 duplication and is often associated with
TOPOIIa expression evaluated by immunohisto-
chemistry.
1
In addition to the fact that ampliﬁcation of HER-2
has become a valid biomarker to identify patients with
breast cancer who respond to HER-2 protein targeting
therapy, several recent clinical trials have found that
HER-2-overexpressing breast cancers,
10 with or with-
out HER-2 ampliﬁcation,
11 are often responsive to
anthracycline-based therapies. In fact, it has been
proposed that HER-2 ampliﬁcation in these tumours
may be a marker of TOPOIIa ampliﬁcation.
12
Recent studies have conﬁrmed that patients with
breast cancer with TOPOIIa gene ampliﬁcation are
more sensitive to TOPOIIa-based therapy.
13 How ever,
it remains controversial whether gene ampliﬁcation
results in overexpression of the TOPOIIa protein.
9,14,15
Adenocarcinoma (ADC) of the oesophagus is cur-
rently the cancer with the fastest increasing incidence
in the USA, and has replaced squamous cell carcinoma
as the most common oesophageal malignancy.
16,17 In
fact, an increase in relative and absolute numbers of
ADCs of the lower third of the oesophagus has been
observed in many Western countries. The most likely
explanation for this ﬁnding seems to be the increasing
prevalence of Barrett’s oesophagus (BO) as a conse-
quence of gastro-oesophageal reﬂux, which is becom-
ing more common with increasing levels of obesity.
The present study was undertaken to investigate: (i)
the role of ampliﬁcation ⁄ overexpression of TOPOIIa
and HER-2 ⁄ neu genes and proteins, (ii) the association
between TOPOIIa ampliﬁcation ⁄ overexpression,
HER-2 ⁄ neu ampliﬁcation ⁄ overexpression and chromo-
some 17 aneusomy, and (iii) the association between
TOPOIIa and HER-2 ⁄ neu ampliﬁcation ⁄ overexpres-
sion and chromosome 17 aneusomy and the presence
of BO, low-grade (LGD) or high-grade dysplasia (HGD)
and ADC.
Patients and methods
patient selection, clinical and endoscopic
evaluation
The clinical records and histological specimens of 44
patients (six women and 38 men, age range
39–89 years) with a conﬁrmed diagnosis of BO were
analysed retrospectively. All patients underwent
surveillance endoscopy at regular intervals or when
clinically indicated at the Digestive Endoscopy Unit of
the University of Brescia. Inclusion criteria were: a
conﬁrmed histological diagnosis of BO, oesophageal
dysplasia (LGD and HGD) and ADC. Overall, specimens
were obtained in 32 patients from biopsies and in 12
patients from mucosectomies.
pathological evaluation
Immediately after sampling, the specimens were ﬁxed in
10% neutral-buffered formalin for 24 h, routinely pro-
cessed in parafﬁn and stained with haematoxylin and
eosin (H&E) and Alcian-periodic acid–Schiff for routine
histological examination. H&E-stained slides from the
resection specimens were evaluated for identiﬁcation of
the steps in cancer progression. ADC and precursor
lesions were diagnosed according to the World Health
Organization classiﬁcation,
18 as previously re-
ported.
19,20 We selected those slides with obvious areas
showingBO(100%showedareaswithBOnotassociated
with dysplasia), LGD (in >90% of the areas), HGD (in
>90%) and ADC (in >90%). The cases of dysplasia were
not associated with an invasive carcinoma.
Serial 3-lm sections were cut for FISH and immu-
nohistochemistry, and the ﬁrst and last sections of
each series were stained with H&E. Corresponding
areas on sequential sections were thus investigated
by the two methods and for both Topo IIa and
Her-2 ⁄ neu.
HER-2 and TOPOIIa status was studied by immuno-
histochemistry and FISH on parafﬁn-embedded tissue.
Numerical alterations of chromosome 17 [chromosome
enumeration probe 17 (CEP17)] were also evaluated by
FISH.
Immunohistochemistry
HER-2 receptor status was studied using the Hercep-
Test kit (DAKOCytomation, Carpinteria, CA, USA).
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turer, tissue sections mounted on slides and stored at
room temperature (25 C) were stained within 4–
6 weeks from sectioning, in order to preserve the
antigenicity, then the samples were counterstained
with Mayer’s haematoxylin. HER-2 oncoprotein
expression was assessed by two investigators (E.R.,
V.V.), following the scoring system recommended by
the manufacturer’s instructions and the Food and Drug
Administration (FDA) guidelines, according to the
Hercep Test
  criteria.
21,22 Immunoreactivity was
scored as follows: 3+, complete and intense membra-
nous reactivity of >10% of tumour cells; 2+, complete
but moderate reactivity of >10% of cells; 1+, weak and
incomplete reactivity in >10% of cells; and 0, no
membranous reactivity, or reactivity in <10% of cells.
To evaluate TOPOIIa protein expression, formalin-
ﬁxed, 3 lm thick parafﬁn-embedded tissues were cut,
mounted on charged slides, and dried. For immunohis-
tochemistry, slides were deparafﬁnized and rehydrated
in graded solutions of ethanol and distilled water.
Endogenous peroxidase was blocked by incubation with
Peroxidase Block and Protein Block (NovoLink Polymer
Detection System; Novocastra Laboratories, Newcastle,
UK) at room temperature, both for 5 min. The immu-
nohistochemical method involved sequential applica-
tion of primary antibody to TOPOIIa (H-231, a rabbit
polyclonal antibody raised against amino acids 1301–
1531 of TOPOIIa of human origin; Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA, USA) diluted 1:50 for
45 min, then post primary block (NovoLink Polymer
Detection System; Novocastra Laboratories) was applied
at room temperature for 15 min and a NovoLink
Polymer (NovoLink Polymer Detection System;
Novocastra Laboratories) for another 15 min. The
immunoprecipitate was visualized by treatment with
3¢3-diaminobenzidine chromogen (NovoLink Polymer
Detection System; Novocastra Laboratories) for 5 min
and counterstained by haematoxylin (Dako). Immuno-
reactivity was considered positive for TOPOIIa when at
least 10% of dysplastic ⁄ neoplastic cells were stained.
We applied the same criteria proposed for the quanti-
ﬁcation of p53 in endometrial and breast carcino-
mas.
23,24 All samples were scored quantitatively and
qualitatively at ·40 high-power ﬁelds (HPF) in every
section (Nikon Eclipse E400, Tokyo, Japan) (Area of
high-power ﬁeld = 0.146 mm
2). TOPOIIa was consid-
ered positive when it could be recognized as a nuclear
brown stain by immunohistochemistry.
FISH
A FDA approved kit for HER-2 evaluation (PathVysion
HER-2 DNA Probe Kit; Vysis Inc., Downers Grove, IL,
USA) was used, according to the manufacturer’s
recommendations. The kit consists of directly labelled
ﬂuorescent DNA probes speciﬁc for the Her-2 ⁄ neu gene
locus (17q11.2-q12), labelled by Spectrum Orange
(SO) and a DNA probe speciﬁc for the a satellite DNA
sequence at the centromeric region of chromosome 17
(17p11.1-q11.1), labelled by Spectrum Green (SG).
TOPOIIa gene was labelled by a locus-speciﬁc iden-
tiﬁer probe for D17Z1 mixed with a probe speciﬁc for
the centromeric region of chromosome 17 (17p11.1-
q11.1) (LSI TOPO2A SO ⁄ CEP17 SG; Vysis Inc.). We
applied the same protocol and scoring for both HER-2
and TOPOIIa.
Counterstaining of nuclei was performed using
4,6-diamidino-2-phenylindole. A special ampliﬁcation
pattern as Her-2 ⁄ neu ‘signal clusters’, usually with
>10 conﬂuent signals, was observed, as previously
described.
25,26 Although gene ampliﬁcation as ‘homo-
geneously stained regions’ was clearly evident, this
pattern did not allow precise signal enumeration. Thus,
the whole area of each neoplastic lesion present in the
tissue section was independently evaluated by two
investigators (E.R., V.V.) with ﬂuorescence microscopy
(Nikon Optiphot-2, Florence, Italy) equipped with
selective ﬁlters for the ﬂuorochromes used, in HPF
(magniﬁcation 600·). FISH images were captured and
elaborated using Genikon software (Nikon Instruments
S.p.A, Florence, Italy). The Her-2 ⁄ neu gene locus was
classiﬁed as ampliﬁed if there were more than twice the
number of red (SO labelling) Her-2 ⁄ neu signals than
green (SG labelling) centromere 17 signals (ratio >2:1)
per cell nucleus. The presence of more than two
nuclear red signals accompanied by the same number
of nuclear green signals was considered to be indicative
of aneusomy (in this case polysomy) of chromosome 17
(ratio 1:1). Following these criteria
23,27 the cell popu-
lation of each HPF was classiﬁed as displaying disomy,
polysomy or an ampliﬁcation of the Her-2 ⁄ neu gene.
For TOPOIIa and HER-2 genes, control slides for
FISH were bought from the same probe manufacturers
(Vysis, FDA approved), while for immunohistochemical
analysis for HER-2 protein control slides were provided
by the kit used (Dako, FDA approved). For TOPOIIa
immunohistochemical analysis (which is the only
method not FDA approved) we used as control a slide
of breast carcinoma previously shown to be positive
with immunohistochemistry and also conﬁrmed posi-
tive by FISH.
statistical analysis
The associations between TOPOIIa gene ampliﬁca-
tion ⁄ TOPOIIa protein overexpression and HER-2 ⁄ neu
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Case Age Sex Diagnosis IHC HER2 IHC TOPOIIa (%) FISH HER2 ⁄ neu FISH TOPOIIa FISH CEP17
1 47 M BO 1 5 NA NA Disomy
2 64 M BO 1 3 NA NA Disomy
3 39 M BO 0 1 NA NA Disomy
4 78 M BO 0 6 NA NA Disomy
5 56 M BO 1 12.7 NA NA Disomy
6 33 M BO 0 23 NA NA Disomy
7 68 M BO 1 25.3 NA NA Disomy
8 61 F BO 1 33 NA NA Disomy
9 66 M BO 0 3 NA NA Disomy
10 69 F BO 1 55.5 NA NA Disomy
11 84 M BO 0 33 NA NA Disomy
12 74 M BO 1 26.1 NA NA Disomy
13 64 M BO 1 31.2 NA NA Disomy
14 48 M BO 2 40 NA NA Disomy
15 82 M BO 0 8 NA NA Disomy
16 67 M BO 1 40.8 NA NA Disomy
17 52 M BO 0 14.44 NA NA Disomy
18 75 M BO 0 3.20 NA NA Disomy
19 72 F LGD 0 35 NA NA Disomy
20 56 M LGD 0 13 NA NA Disomy
21 74 F LGD 3 96 A A Disomy
22 76 M LGD 3 37 A NA Aneusomy
23 77 M LGD 2 50.2 NA NA Disomy
24 59 M HGD 1 58 NA NA Aneusomy
25 89 M HGD 0 38 NA NA Disomy
26 76 M HGD 3 60 A A Aneusomy
27 48 M HGD 1 44.5 NA NA Disomy
28 85 M HGD 3 90 A A Disomy
29 53 M HGD 3 87 A A Aneusomy
30 82 M HGD 3 100 A A Disomy
31 51 M HGD 3 37 NA NA Disomy
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chromosome 17 aneusomy, and the presence of BO,
dysplasia (LGD or HGD) and ADC were evaluated by the
usual methods for comparison of proportions. Histology
was categorized at three levels: BO, oesophageal
dysplasia (which includes LGD and HGD) and ADC.
Immunohistochemistry for TopoIIa was categorized at
four levels according to quartiles of the percentage:
0–25.0; 25.1–50.0; 50.1–75.0; and 75.1–100%.
P-values <0.05 (two-tailed tests) were used to reject
the null hypothesis. Immunohistochemistry for HER-2
protein was categorized at four levels based on the
FDA’s approved scoring system (0, 1, 2, 3); FISH for
both TOPOIIa and HER-2 ⁄ neu genes was considered
positive when ampliﬁed and negative when not ampli-
ﬁed, and FISH for chromosome 17 was considerate
positive or negative in the presence of chromosome
aneusomy or disomy, respectively.
ethical considerations
Since this was a retrospective study, no individual
patient identiﬁcation was done and no study-driven
clinical intervention was performed. Thus, a simpliﬁed
Institutional Review Board approval for retrospective
studies was obtained and no patient consent was
necessary.
Results
The characteristics of the 44 subjects included in the
study and the results of the overexpression ⁄ ampliﬁca-
tion of the genes investigated are shown in Table 1.
HER-2 ⁄ neu gene copy number was higher because
clusters were identiﬁed (>10 signals), whereas TOPOIIa
copy number was lower because it was often possible to
count the single spots. No deletions were seen in any of
the 44 patients analysed. Almost perfect agreement
(43 ⁄ 44, 98%) was found between FISH TOPOIIa and
HER-2 ⁄ neu gene ampliﬁcation, with the single excep-
tion of subject 22 (P < 0.001).
A statistically signiﬁcant association was found
between immunohistochemical TOPOIIa protein
overexpression and FISH TOPOIIa gene ampliﬁcation
(P < 0.001), FISH HER-2 ⁄ neu gene ampliﬁcation
(P < 0.001), immunohistochemical HER-2 protein
overexpression (P < 0.001) and FISH chromosome
17 aneusomy (P = 0.03). A strong association was
also found between immunohistochemical HER-2
protein overexpression and FISH HER-2 ⁄ neu gene
Table 1. (Continued)
Case Age Sex Diagnosis IHC HER2 IHC TOPOIIa (%) FISH HER2 ⁄ neu FISH TOPOIIa FISH CEP17
32 69 M ADC 1 53 NA NA Aneusomy
33 75 M ADC 3 100 A A Disomy
34 89 M ADC 1 42.3 NA NA Aneusomy
35 67 F ADC 1 84 NA NA Aneusomy
36 83 M ADC 2 49 NA NA Aneusomy
37 78 M ADC 2 43 NA NA Aneusomy
38 80 M ADC 1 49 NA NA Disomy
39 71 F ADC 3 80 A A Aneusomy
40 58 M ADC 3 87 A A Aneusomy
41 76 M ADC 1 65 NA NA Disomy
42 68 M ADC 3 65 A A Disomy
43 77 M ADC 2 97 NA NA Aneusomy
44 73 M ADC 3 75 A A Disomy
M, male; F, female; BO, Barrett’s oesophagus; LGD, low-grade dysplasia; HGD, high-grade dysplasia; ADC, adenocarcinoma;
IHC, immunohistochemistry; FISH, ﬂuorescence in situ hybridization; A, ampliﬁed; NA, not ampliﬁed; CEP, chromosome
enumeration probe.
IHC Her2: values from 0 to 3 were attributed according to Food and Drug Administration instructions.
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ﬁcation (P < 0.001) and FISH aneusomy for chromo-
some17 (P = 0.02). No association was found between
FISH chromosome 17 aneusomy and either FISH HER-
2 ⁄ neu or TOPOIIa gene ampliﬁcation (P > 0.1 for
both).
Table 2 shows the distribution of the three groups of
subjectsaccordingtoeachgene ⁄ proteinassessmentand
chromosome aneusomy ⁄ disomy. Gene ampliﬁcation
(FISH HER-2 ⁄ neu and TOPOIIa), protein overexpression
(HER-2, TOPOIIa) and chromosome 17 aneusomy were
allassociatedwiththepresenceofdysplasiaorADCwith
respect to BO (P < 0.05 for each comparison). Among
subjects with BO, none showed HER-2 ⁄ neu or TOPOIIa
ampliﬁcation or chromosome 17 aneusomy, and almost
none had moderate to complete membranous immuno-
reactivity for HER-2 protein expression (immunohisto-
chemistry) (score 2 or 3) or >50% TOPOIIa protein
expression (immunohistochemistry) (quartiles 3–4). On
the other hand, 30–61% of subjects with dysplasia or
ADC showed gene ampliﬁcation and protein overexpres-
sion for both HER-2 ⁄ neu or TOPOIIa and chromosome
17 aneusomy. No signiﬁcant differences in positivity
were seen between dysplasia and ADC for any the
Table 2. Distribution of subjects according to gene ampliﬁcation, protein expression and histology
Chromosome 17 genes ⁄
proteins
Histology
All pathologies
P-value*
BO
Dysplasia
(LGD-HGD) ADC
No. (%) No. (%) No. (%) No. (%)
Total subjects 18 (100) 13 (100) 13 (100) 44 (100)
HER-2 protein (IHC)
0 8 (44.4) 3 (23.1) 0 (–) 11 (25.0) 0.001
1 9 (50.0) 3 (23.1) 5 (38.5) 17 (38.6)
2 1 (5.6) 1 (7.7) 3 (23.1) 5 (11.4)
3 0 (–) 6 (46.2) 5 (38.5) 11 (25)
HER-2 ⁄ neu gene (FISH)
0 (NA) 18 (100) 7 (53,8) 8 (61.5) 33 (75) 0.002
1 (A) 0 (–) 6 (46) 5 (38.4) 11 (25)
Chromosome 17 (FISH)
0 (Disomy) 18 (100) 9 (69.2) 5 (38.5) 32 (72.7) 0.004
1 (Aneusomy) 0 (–) 4 (30.8) 8 (61.5) 12 (27.3)
TopoIIa protein (IHC)
1 (1.0–25.0%) 10 (55.5) 1 (7.7) 0 (–) 11 (25) 0.001
2 (25.1–50%) 7 (38.9) 5 (38.44) 4 (30.8) 16 (36.3)
3 (50.1–75%) 1 (5.55) 3 (23) 4 (30.8) 8 (18.1)
4 (75.1–100%) 0 (–) 4 (30.8) 5 (38.44) 9 (20.4)
TopoIIa gene (FISH)
0 (NA) 18 (100) 8 (61.5) 8 (61.55) 34 (77.3) 0.004
1 (A) 0 (–) 5 (38.4) 5 (38.44) 10 (22.7)
BO, Barrett’s oesophagus; LGD, low-grade dysplasia; HGD, high-grade dysplasia; ADC, adenocarcinoma; IHC, immunohis-
tochemistry; FISH, ﬂuorescence in situ hybridization; A, ampliﬁed; NA, not ampliﬁed.
*Exact tests for the comparison among proportions of patients with BO, dysplasia and ADC for each gene overexpression ⁄
ampliﬁcation.
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Figures 1 and 2.
With the single exception of case 22, all the cases of
dysplasia and ADC showed co-ampliﬁcation of TOPOIIa
and HER-2 ⁄ neu genes (>50%). HER-2 ⁄ neu gene ampli-
ﬁcationwashigherthenTOPOIIa(Figure 1D)becauseof
theclustering(>10signals)(Figure 2B),asalsoreported
in previously.
3,4,28 No deletions were seen in any of the
44 patients analysed. There was no signiﬁcant associa-
tion between protein ⁄ gene overexpression ⁄ ampliﬁca-
tion and age or gender (data not shown).
Discussion
Topoisomerases are nuclear enzymes that regulate
cellular processes such as replication and transcription;
in addition, these enzymes represent a major molecular
target for drugs of the anthracycline class or chemo-
therapeutic agents.
9 Clinical and in vitro evidence
supports the concept that in breast cancer the associ-
ation between HER-2 ampliﬁcation and response to
anthracycline-based chemotherapy is not a direct effect
of HER-2 overexpression but the result of co-ampliﬁca-
tion of the TOPOIIa gene.
29 Some studies have shown
that increased expression of TOPOIIa in BO is associ-
ated with HGD,
30 as well as the fact that HER-2 is
overexpressed in oesophageal ADC
31 and this overex-
pression may predict early transition from dysplasia to
ADC in BO.
32 However, to the best of our knowledge
the expression of TOPOIIa and HER-2 has not been
previously investigated in BO patients.
In the present study we examined HER-2 ⁄ neu and
TOPOIIa gene ⁄ protein by FISH and immunohisto-
chemistry, respectively, and we also investigated chro-
AB
CD
Figure 1. A,B, Immunohistochemistry for TOPOIIa. A, right part: normal oesophagus largely negative for TOPOIIa; only in the basal layer is it
possible to recognize some positive cells. On the left is an area of dysplasia where the positivity increases (case 22, Table 1). B, Area of high-grade
dysplasia, where the cells are positive for TOPOIIa (case 30, Table 1). C,D, Fluorescence in situ hybridization for TOPOIIa. C, A normal
oesophagus displays two signals for TOPOIIa (red spots) and for chromosome17 (green spots). D, Low-grade dysplasia with gene ampliﬁcation
(patient 22, Table 1).
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HGD and ADC).
In agreement with previous studies on breast
carcinomas,
3 we conﬁrmed that TOPOIIa is rarely
ampliﬁed in the absence of HER-2 ampliﬁcation, that
it is co-ampliﬁed with HER-2 in dysplasia (LGD and
HGD) and ADC, and that the HER-2 gene copy
number, because of clustering, was higher than the
TOPOIIa copy number. Moreover, statistically signiﬁ-
cant associations were found between gene ampliﬁca-
tion and protein expression for both HER-2 and
TOPOIIa, between HER-2 and TOPOIIa gene ampliﬁ-
cation and between HER-2 and TOPOIIa protein
expression, conﬁrming the results of previous studies
regarding pancreatic and gastric cancers.
2,4 Chromo-
some 17 aneusomy was found to be associated with
TOPOIIa protein overexpression but not with each
gene ampliﬁcation. No deletions for TOPOIIa and ⁄ or
HER-2 ⁄ neu were seen in any of our patients, whereas
monoallelic deletions were found in other pathological
conditions, i.e. breast cancer.
3
We investigated the associations between the
above-mentioned markers and pathological ﬁndings.
We found HER-2 ⁄ TOPOIIa gene ampliﬁcation ⁄ protein
overexpression and chromosome 17 aneusomy (poly-
somy) in a high proportion of patients with dysplasia
(LGD and HGD) or ADC, but in almost none of the
patients with BO, suggesting involvement of these
factors in cancer development. It is well known that BO
is associated with gastrointestinal acid reﬂux, and it has
been suggested that acid reﬂux could introduce muta-
tions in oesophageal cells due to acid pH-induced DNA
damage.
33 However, acid reﬂux also causes inﬂamma-
tory responses known to contribute to carcinogenesis.
34
Recent clinical studies have shown that TOPOIIa
gene ampliﬁcation is a more speciﬁc predictor than
TOPOIIa expression assessed by immunohistochemis-
try and HER-2 gene ampliﬁcation for clinical response
to TOPOIIa inhibitors in breast cancer.
35 For this
reason, FISH testing for TOPOIIa status in addition to
HER-2 evaluation may be useful in the characterization
of Barrett’s pathology and progression to dysplasia.
Furthermore, ascertaining TOPOIIa status might be
useful to select patients for combination therapy: a trial
could be designed to investigate whether patients with
TOPOIIa ampliﬁcation may be treated with HER-2
targeting drug together with a cytotoxic drug, such as
TOPOIIa-inhibitor.
In conclusion, these ﬁndings suggest that the
investigation of these markers might be useful in
characterizing the evolution from BO to dysplasia and
ADC. These potential markers might also contribute to
deciding alternative therapeutic approaches, as
suggested by some preliminary data.
36
Acknowledgements
The authors thank Professors Vanio Vannini and
Cesare Danesino (University of Pavia), tutors of E.R.
for the PhD in Pathology and Genetics, and Ms Anna
Galletti, Ms Lucia Fontana and Ms Monica Brotto for
providing technical support. E.R. is recipient of a grant
from Ingenio Finlombarda S.p.a., Regione Lombardia,
Italy.
References
1. Murphy AJ, Hughes CA, Barrett C et al. Low-level TOP2A
ampliﬁcation in prostate cancer is associated with HER2 dupli-
cation, androgen resistance, and decreased survival. Cancer Res.
2007; 15; 2893–2898.
A
B
Figure 2. A,B, Case 29. HER-2 analysed respectively by immuno-
histochemistry and ﬂuorescence in situ hybridization. A, All the areas
of dysplasia are positive for the membranous stain which identiﬁes
HER-2 receptor. B, The same area of dysplasia. HER-2 gene
ampliﬁcation (red spots) is strong and shows typical clusters;
chromosome17 aneusomy is present in all the nuclei with more than
two green signals.
88 E Rossi et al.
  2010 Blackwell Publishing Ltd, Histopathology, 57, 81–89.2. Hansel DE, Ashfaq R, Rahman A et al. A subset of pancreatic
adenocarcinomas demonstrates coampliﬁcation of topoisomerase
IIalpha and HER2 ⁄ neu: use of immunolabeling and multicolor
FISH for potential patient screening and treatment. Am. J. Clin.
Pathol. 2005; 123; 28–35.
3. Bouchalova ´ K, Trojanec R, Kola ´rZet al. Analysis of ERBB2 and
TOP2A gene status using ﬂuorescence in situ hybridization
versus immunohistochemistry in localized breast cancer. Neopl-
asma 2006; 53; 393–401.
4. Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A.
Topoisomerase IIalpha gene ampliﬁcation in gastric carcinomas:
correlation with the HER2 gene. An immunohistochemical,
immunoblotting, and multicolor ﬂuorescence in situ hybridiza-
tion study. Hum. Pathol. 2006; 10; 1333–1343.
5. Al-Kuraya K, Novotny H, Bavi P et al. HER2, TOP2A, CCND1,
EGFR and C-MYC oncogene ampliﬁcation in colorectal cancer. J.
Clin. Pathol. 2007; 60; 768–772.
6. Ross JS, Fletcher JA. The HER-2 ⁄ neu oncogene in breast cancer:
prognostic factor, predictive factor, and target for therapy. Stem
Cells 1998; 16; 413–428.
7. Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross JS. HER-
2 ⁄ neu gene ampliﬁcation by FISH predicts poor survival in
Barrett’s esophagus-associated adenocarcinoma. Hum. Pathol.
2000; 31; 35–39. Erratum in: Hum. Pathol. 2000; 31; 524.
8. Isaacs RJ, Davies SL, Wells NJ, Harris AL. Topoisomerases II
alpha and beta as therapy targets in breast cancer. Anticancer
Drugs 1995; 6; 195–211.
9. Jarvinen TA, Tanner M, Rantanen V et al. Ampliﬁcation and
deletion of topoisomerase IIalpha associate with ErbB-2 ampli-
ﬁcation and affect sensitivity to topoisomerase II inhibitor
doxorubicin in breast cancer. Am. J. Pathol. 2000; 156; 839–
847.
10. Paik S, Bryant J, Tan-Chiu E et al. HER2 and choice of adjuvant
chemotherapy for invasive breast cancer: National Surgical
Adjuvant Breast and Bowel Project Protocol B-15. J. Natl Cancer
Inst. 2000; 92; 1991–1998.
11. Thor AD, Berry DA, Budman DR et al. erbB-2, p53, and efﬁcacy
of adjuvant therapy in lymph node-positive breast cancer. J. Natl
Cancer Inst. 1998; 90; 1346–1360.
12. Lynch BJ, Guinee DG Jr, Holden JA. Human DNA topoisomerase
II-alpha: a new marker of cell proliferation in invasive breast
cancer. Hum. Pathol. 1997; 28; 1180–1188.
13. Di Leo A, Gancberg D, Larsimont D et al. HER-2 ampliﬁcation
and topoisomerase IIalpha gene aberrations as predictive mark-
ers in node-positive breast cancer patients randomly treated
either with an anthracycline-based therapy or with cyclophos-
phamide, methotrexate, and 5-ﬂuorouracil. Clin. Cancer Res.
2002; 8; 1107–1116.
14. Coon JS, Marcus E, Gupta-Burt S et al. Ampliﬁcation and
overexpression of topoisomerase IIalpha predict response to
anthracycline-based therapy in locally advanced breast cancer.
Clin. Cancer Res. 2002; 8; 1061–1067.
15. Mueller RE, Parkes RK, Andrulis I, O’Malley FP. Ampliﬁcation of
the TOP2A gene does not predict high levels of topoisomerase II
alpha protein in human breast tumor samples. Genes Chromo-
somes Cancer 2004; 39; 288–297.
16. Paulson TG, Reid BJ. Focus on Barrett’s esophagus and esoph-
ageal adenocarcinoma. Cancer Cell 2004; 6; 11–16.
17. DeMeester SR. Adenocarcinoma of the esophagus and cardia: a
review of the disease and its treatment. Ann. Surg. Oncol. 2006;
13; 12–30.
18. Hamilton SR, Aaltonen LA. WHO pathology and genetics: tumors of
digestive system. Lyon: IARC Press, 2000.
19. Villanacci V, Rossi E, Zambelli C et al. COX-2, CDX2, and CDC2
immunohistochemical assessment for dysplasia–carcinoma pro-
gression in Barrett’s esophagus. Dig. Liver Dis. 2007; 39; 305–
311.
20. Villanacci V, Bellone G, Battaglia E et al. Ski ⁄ SnoN expression in
the sequence metaplasia–dysplasia–adenocarcinoma of Barrett’s
esophagus. Hum. Pathol. 2008; 39; 403–409.
21. Ellis IO, Dowsett M, Bartlett J et al. Recommendations for HER2
testing in the UK. J. Clin. Pathol. 2000; 53; 890–892.
22. Dowsett M, Hanna WM, Kockx M et al. Standardization of HER2
testing: results of an international proﬁciency-testing ring study.
Mod. Pathol. 2007; 20; 584–591.
23. McCarthy NJ, Yang X, Linnoila IR et al. Microvessel density,
expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2
in inﬂammatory breast cancer. Clin. Cancer Res. 2002; 8; 3857–
3862.
24. Mazurek A, Pierzyn ´ski P, Kuc ´ P et al. Evaluation of angiogenesis,
p-53 tissue protein expression and serum VEGF in patients with
endometrial cancer. Neoplasma 2004; 51; 193–197.
25. Ishikawa T, Kobayashi M, Mai M, Suzuki T, Ooi A. Ampliﬁcation
of the c-erbB-2 (HER-2 ⁄ neu) gene in gastric cancer cells.
Detection by ﬂuorescence in situ hybridization. Am. J. Pathol.
1997; 151; 761–768.
26. Walch A, Bink K, Gais P et al. Evaluation of c-erbB-2
overexpression and Her-2 ⁄ neu gene copy number heterogeneity
in Barrett’s adenocarcinoma. Anal. Cell. Pathol. 2000; 20; 25–32.
27. Ellis IO, Bartlett J, Dowsett M et al. Best practice no 176: updated
recommendations for HER2 testing in the UK. J. Clin. Pathol.
2004; 57; 233–237.
28. Bru ¨derlein S, van der Bosch K, Schlag P, Schwab M. Cytogenetics
and DNA ampliﬁcation in colorectal cancers. Genes Chromosomes
Cancer 1990; 2; 63–70.
29. Hicks DG, Yoder BJ, Pettay J et al. The incidence of topoisomerase
II-alpha genomic alterations in adenocarcinoma of the breast
and their relationship to human epidermal growth factor
receptor-2 gene ampliﬁcation: a ﬂuorescence in situ hybridization
study. Hum. Pathol. 2005; 36; 348–356.
30. Sabo E, Meitner PA, Tavares R et al. Expression analysis of
Barrett’s esophagus-associated high-grade dysplasia in laser
capture microdissected archival tissue. Clin. Cancer Res. 2008;
14; 6440–6448.
31. Rauser S, Weis R, Braselmann H et al. Signiﬁcance of HER2 low-
level copy gain in Barrett’s cancer: implications for ﬂuorescence
in situ hybridization testing in tissues. Clin. Cancer Res. 2007; 13;
5115–5123.
32. Rossi E, Grisanti S, Villanacci V et al. HER-2 overexpres-
sion ⁄ ampliﬁcation in Barrett’s esophagus predicts early transi-
tion from dysplasia to adenocarcinoma: a clinico-pathologic
study. J. Cell Mol. Med. 2009; 13; 3826–3833.
33. Wild CP, Hardie LJ. Reﬂux, Barrett’s oesophagus and
adenocarcinoma: burning questions. Nat. Rev. Cancer 2003; 3;
676–684.
34. Schottenfeld D, Beebe-Dimmer J. Chronic inﬂammation: a com-
mon and important factor in the pathogenesis of neoplasia. CA
Cancer J. Clin. 2006; 56; 69–83.
35. Di Leo A, Isola J. Topoisomerase II alpha as a marker
predicting the efﬁcacy of anthracyclines in breast cancer: are
we at the end of the beginning? Clin. Breast Cancer 2003; 4;
179–186.
36. Villanacci V, Rossi E, Grisanti S et al. Targeted therapy with
trastuzumab in dysplasia and adenocarcinoma arising in Bar-
rett’s esophagus: a translational approach. Minerva Gastroenterol.
Dietol. 2008; 54; 347–353.
TopoIIa and Her-2 in Barrett’s oesophagus 89
  2010 Blackwell Publishing Ltd, Histopathology, 57, 81–89.